Moises Eisenberg-Grunberg

Title: Moises Eisenberg-Grunberg: Innovator in Amyloid Detection

Introduction

Moises Eisenberg-Grunberg is a notable inventor based in Port Jefferson Station, NY (US). He has made significant contributions to the field of biomedical research, particularly in the detection of amyloid beta-protein, which is crucial for understanding various neurodegenerative diseases.

Latest Patents

Eisenberg-Grunberg holds a patent for "Methods for the detection of soluble amyloid .beta.-protein (.beta.AP)." This invention focuses on methods and compositions aimed at preventing the aggregation of amyloid beta-protein. The aggregation of this protein is linked to the deposition of amyloid in the brain, which is associated with conditions such as Alzheimer's disease. His patent describes amyloid beta-protein-binding compounds, such as transthyretin, which form complexes with beta-AP to prevent amyloid formation. Additionally, the invention identifies the serine 6 mutation in the TTR gene as a predictive marker for individuals at risk of developing beta-AP associated amyloidosis.

Career Highlights

Eisenberg-Grunberg is affiliated with The State University of New York, where he continues to engage in research and innovation. His work has garnered attention for its potential impact on diagnosing and treating amyloid-related conditions.

Collaborations

Some of his notable coworkers include Dmitry Y Goldgaber and Alexander L Schwarzman. Their collaborative efforts contribute to advancing research in the field of amyloid detection and treatment.

Conclusion

Moises Eisenberg-Grunberg's innovative work in the detection of amyloid beta-protein highlights his commitment to addressing critical health challenges. His contributions are paving the way for advancements in understanding and treating neurodegenerative diseases.